Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 June 2025 | Story Lacea Loader | Photo Supplied
Prof Philippe Burger
Prof Philippe Burger, Dean of the Faculty of Economic and Management Sciences at the University of the Free State, appointed to the DHET Expert Panel on University Fees to help shape the future of tuition affordability and sustainability in South Africa.

Prof Philippe Burger, Dean: Faculty of Economic and Management Sciences at the University of the Free State (UFS), has been appointed as a member of a team that will represent Universities South Africa (USAf) in a DHET Expert Panel on University Fees. The panel, which comprises representatives from USAf, the DHET, and NSFAS, focuses on the affordability of tuition fees and the future sustainability of the sector, looking at potential solutions for tuition fees beyond the 2025 academic year. 

With more than 30 years of experience in higher education, mostly in management positions, Prof Burger understands the sector well. Combined with his expertise in macroeconomics, fiscal policy, and public sector economics and finance, he is uniquely positioned to make a significant contribution to this task team.

 

Universities matter

Despite the high national unemployment rate (32%), Prof Burger points out that unemployment is largely a problem of the unskilled. “The unemployment rate of people with university degrees is about 12%, much lower than the national average,” he notes. “South Africa has a large shortage of skilled labour, which it needs to grow the economy and improve lives.” He trusts that universities can fill this void, in addition to providing the thought leaders needed to take the country forward.

Although universities in South Africa are experiencing financial pressures, they continue to lift thousands of people to better lives each year. Universities make a profoundly positive contribution to the country and its population, and Prof Burger believes that once the public is fully aware of this, it will support broader discussions in favour of higher education.

 

The challenge

Universities face several cost pressures that are causing an increase in cost at a higher rate than consumer inflation, Prof Burger explains. “For instance, we buy equipment, software, and journal subscriptions that are all priced in US dollars. Affected by the exchange rate, these types of expenses have increased by much more than the price of consumer goods in South Africa over the past ten years.” According to Prof Burger, increased operational costs, coupled with constrained university income, necessitate a model that will provide universities with enough income to cover their costs while delivering quality education in the long run. 

 

The solution

“There is an argument for universities to become more efficient, and there is certainly room for universities to look at their cost structures, but there is also a limit to what we can do,” Prof Burger says. “It is important to stress that we cannot talk about the sustainability of universities and not contextualise it within a framework that seeks to deliver quality learning, teaching, and research. In the absence of that quality, we will not be able to address the skills shortages and thought leadership that the country needs. And that is the sustainability we need to talk about – the sustainability of quality education and scholarship,” he concludes. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept